Factors affecting plasma retinol decline during long-term administration of the synthetic retinoid Fenretinide in breast cancer patients

Rosalba Torrisi, Stefano Parodi, Vincenzo Fontana, Gabriella Rondanina, Franca Formelli, Alberto Costa, Francesco Boccardo, Andrea Decensi

Research output: Contribution to journalArticle

Abstract

Administration of the synthetic retinoid Fenretinide lowers circulating retinol and may thus affect night vision. We have recently shown that plasma retinol levels below 100 ng/ml are associated with moderate alterations of the dark adaptometry test. To identify which patients are more likely to experience a decrease of plasma retinol under this threshold, we measured plasma levels of retinol, Fenretinide, and its metabolite 4-MPR in a cohort of 28 women receiving Fenretinide at the daily dose of 200 mg and studied their relationship with clinical characteristics such as age, menstrual status, body mass index, and time on treatment. Our results show that patients aged over 55 years with a higher percentage of adipose tissue had higher plasma concentrations of 4-MPR, which turned out to be the major determinant of the retinol decrease. This subgroup may thus deserve careful ophthalmological surveillance.

Original languageEnglish
Pages (from-to)507-510
Number of pages4
JournalCancer Epidemiology Biomarkers and Prevention
Volume3
Issue number6
Publication statusPublished - 1994

Fingerprint

Fenretinide
Retinoids
Vitamin A
Breast Neoplasms
Night Vision
Adipose Tissue
Body Mass Index

ASJC Scopus subject areas

  • Epidemiology
  • Oncology

Cite this

Factors affecting plasma retinol decline during long-term administration of the synthetic retinoid Fenretinide in breast cancer patients. / Torrisi, Rosalba; Parodi, Stefano; Fontana, Vincenzo; Rondanina, Gabriella; Formelli, Franca; Costa, Alberto; Boccardo, Francesco; Decensi, Andrea.

In: Cancer Epidemiology Biomarkers and Prevention, Vol. 3, No. 6, 1994, p. 507-510.

Research output: Contribution to journalArticle

@article{497a9b2a6a944c878babf69f53df4f99,
title = "Factors affecting plasma retinol decline during long-term administration of the synthetic retinoid Fenretinide in breast cancer patients",
abstract = "Administration of the synthetic retinoid Fenretinide lowers circulating retinol and may thus affect night vision. We have recently shown that plasma retinol levels below 100 ng/ml are associated with moderate alterations of the dark adaptometry test. To identify which patients are more likely to experience a decrease of plasma retinol under this threshold, we measured plasma levels of retinol, Fenretinide, and its metabolite 4-MPR in a cohort of 28 women receiving Fenretinide at the daily dose of 200 mg and studied their relationship with clinical characteristics such as age, menstrual status, body mass index, and time on treatment. Our results show that patients aged over 55 years with a higher percentage of adipose tissue had higher plasma concentrations of 4-MPR, which turned out to be the major determinant of the retinol decrease. This subgroup may thus deserve careful ophthalmological surveillance.",
author = "Rosalba Torrisi and Stefano Parodi and Vincenzo Fontana and Gabriella Rondanina and Franca Formelli and Alberto Costa and Francesco Boccardo and Andrea Decensi",
year = "1994",
language = "English",
volume = "3",
pages = "507--510",
journal = "Cancer Epidemiology Biomarkers and Prevention",
issn = "1055-9965",
publisher = "American Association for Cancer Research Inc.",
number = "6",

}

TY - JOUR

T1 - Factors affecting plasma retinol decline during long-term administration of the synthetic retinoid Fenretinide in breast cancer patients

AU - Torrisi, Rosalba

AU - Parodi, Stefano

AU - Fontana, Vincenzo

AU - Rondanina, Gabriella

AU - Formelli, Franca

AU - Costa, Alberto

AU - Boccardo, Francesco

AU - Decensi, Andrea

PY - 1994

Y1 - 1994

N2 - Administration of the synthetic retinoid Fenretinide lowers circulating retinol and may thus affect night vision. We have recently shown that plasma retinol levels below 100 ng/ml are associated with moderate alterations of the dark adaptometry test. To identify which patients are more likely to experience a decrease of plasma retinol under this threshold, we measured plasma levels of retinol, Fenretinide, and its metabolite 4-MPR in a cohort of 28 women receiving Fenretinide at the daily dose of 200 mg and studied their relationship with clinical characteristics such as age, menstrual status, body mass index, and time on treatment. Our results show that patients aged over 55 years with a higher percentage of adipose tissue had higher plasma concentrations of 4-MPR, which turned out to be the major determinant of the retinol decrease. This subgroup may thus deserve careful ophthalmological surveillance.

AB - Administration of the synthetic retinoid Fenretinide lowers circulating retinol and may thus affect night vision. We have recently shown that plasma retinol levels below 100 ng/ml are associated with moderate alterations of the dark adaptometry test. To identify which patients are more likely to experience a decrease of plasma retinol under this threshold, we measured plasma levels of retinol, Fenretinide, and its metabolite 4-MPR in a cohort of 28 women receiving Fenretinide at the daily dose of 200 mg and studied their relationship with clinical characteristics such as age, menstrual status, body mass index, and time on treatment. Our results show that patients aged over 55 years with a higher percentage of adipose tissue had higher plasma concentrations of 4-MPR, which turned out to be the major determinant of the retinol decrease. This subgroup may thus deserve careful ophthalmological surveillance.

UR - http://www.scopus.com/inward/record.url?scp=0028068071&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028068071&partnerID=8YFLogxK

M3 - Article

C2 - 8000302

AN - SCOPUS:0028068071

VL - 3

SP - 507

EP - 510

JO - Cancer Epidemiology Biomarkers and Prevention

JF - Cancer Epidemiology Biomarkers and Prevention

SN - 1055-9965

IS - 6

ER -